The Platin-X series: activation, targeting, and delivery
Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the “magic bullet” which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(IV) complexes are kinetically more inert than the Pt(II) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(IV) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.
- This article is part of the themed collection: Metallodrugs: Activation, Targeting, and Delivery